tumors

Creating Cutting-Edge Cancer Vaccines

IRP Research Identifies a Tantalizing Target for Cancer Immunotherapy

person getting vaccine injection

February 4 is World Cancer Day, a time to mark international efforts to prevent, detect, and treat cancer. Immunotherapy, one of the most significant advances in treating cancer, was pioneered here at NIH more than 30 years ago. Today, IRP senior investigator Claudia M. Palena, Ph.D., is pushing cancer immunotherapy forward with the discovery of a novel target for cancer vaccines.

Graduate Student Symposium Spotlights Future Scientists

IRP’s Ph.D. and Medical Students Present Research at Virtual Event

Khiem Lam

The IRP isn’t concerned only with discovering the secrets of how our bodies work and developing new therapies to treat disease. Senior scientists and many other employees at NIH also are actively involved in training the next generation of researchers. One place where the benefits of those efforts is strikingly clear is at NIH’s annual Graduate Student Research Symposium, where graduate students performing research in NIH labs show of the fruits of their partnerships with IRP researchers.

On February 16 and 17, more than 100 of the IRP’s graduate students presented their work virtually at the 18th edition of the event. These young scientists discussed the results of studies on a huge range of topics, from how hunger changes during pregnancy to how viruses cause cancer. Read on to learn about a small sampling of the projects they’ve been hard at work on.

Breakthrough Treatment Brings Hope to Children with Tumor Disorder

Brigitte Widemann Recognized for Pioneering Work on Debilitating Disease

Dr. Brigitte C. Widemann

Getting diagnosed with a serious illness as an adult can be devastating, so one can hardly imagine the impact of receiving such news as a child, particularly when the disease has no good treatments. Until recently, this was the case for many children with the potentially severe and frequently disfiguring condition neurofibromatosis type 1 (NF1). However, pioneering research led by IRP senior investigator Brigitte C. Widemann, M.D., led to the first-ever drug approved by the U.S. Food and Drug Administration (FDA) to treat the condition. For this groundbreaking work, Dr. Widemann, her IRP research team, and her collaborators outside NIH were named as finalists for the 2020 Samuel J. Heyman Service to America Medals, also known as the ‘Sammies,’ an award that honors exceptional work by government employees.

A Summer Dive Into NIH History

With summer winding down, it's about time we took another dive into some NIH history! These new additions to the NIH Stetten Museum collection feature some of the most prominent investigators ever to walk the NIH campus, including a Nobel prize winner and a scientist who made important discoveries about how electricity travels between neurons.

Dr. Marshall Nirenberg

Honoring Two Legendary IRP Scientists

ribbon cutting at the exhibit's opening

NIH history is rife with legends, scientists who have made remarkable discoveries and incalculable contributions to the health and longevity of humankind. There are living legends; just peruse the “Honors” page on the IRP website to see what I mean. And there are greats who are gone but certainly not forgotten.

Summertime Brains: Francia Fang

Francia Fang, who is currently a junior at Duke University, spent her 2017 summer working in the lab of NIH IRP Senior Investigator Dr. Zhengping Zhuang. During her time at the NIH, Fang investigated how genes influence the development of brain tumors and also shadowed doctors as they met with brain cancer patients.

The video above, featuring Fang, is the first in a series of profiles highlighting IRP summer interns who worked in NIH National Institute of Neurological Disorders and Stroke (NINDS) intramural labs this past summer.

Early Women Scientists of NIH, Part 2

Margaret Kelly, NCI NIH

Like many in the second wave of women scientists at the National Institutes of Health, Dr. Margaret Kelly began as a technician and got her PhD while she was working. Kelly focused on what caused cancer and what drugs could be used to fight it.